Computer-aided identification of novel anticancer compounds with a possible dual HER1/HER2 inhibition mechanism

被引:10
|
作者
Elseginy, Samia A. [1 ,2 ]
Lazaro, Glorianne [1 ]
Nawwar, Galal A. M. [2 ]
Amin, Kamilia M. [3 ]
Hiscox, Stephen [1 ]
Brancale, Andrea [1 ]
机构
[1] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff CF10 3NB, S Glam, Wales
[2] Natl Res Ctr, Green Chem Dept, Cairo, Egypt
[3] Cairo Univ, Dept Pharmaceut Chem, Cairo, Egypt
关键词
HER1; EGFR; HER2; Virtual screening structure-based drug design; GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; TYROSINE KINASE INHIBITOR; ANTITUMOR-ACTIVITY; OVARIAN-CANCER; IN-VIVO; HER2; TRASTUZUMAB; ANTIBODY; THERAPY;
D O I
10.1016/j.bmcl.2014.12.095
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
HER1 and HER2 are frequently overexpressed in human tumors where they drive cellular proliferation. For this reason they are considered important targets in anticancer therapy with dual HER1/HER2 inhibitors being recently approved and marketed. In this paper we report the identification of a series of compounds with anticancer activity by a combined virtual screening approach on the kinase domains of HER1 and HER2. 6 hit compounds that present a sub- or low-micromolar activity in two cell-based assays, were initially identified and a subsequent design cycle led to the synthesis of a compound with nanomolar activity in the cell-based assays. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:758 / 762
页数:5
相关论文
共 50 条
  • [1] A novel dual inhibitor of HER1 and HER2 protein tyrosine kinases
    Mastalerz, H
    Dextraze, P
    Gavai, A
    Johnson, W
    Lee, F
    Oppenheimer, S
    Ruediger, E
    Tarrant, J
    Vite, G
    Vyas, D
    Wong, TW
    Zhang, GF
    Zhang, HJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2717 - U2717
  • [2] Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
    Reid, Alison
    Vidal, Laura
    Shaw, Heather
    de Bono, Johann
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (03) : 481 - 489
  • [3] Exploration of an aminothiazole dual HER2/HER1 kinase inhibitor.
    Mastalerz, H
    Chang, M
    Johnson, W
    Kadow, J
    Langley, D
    Vite, G
    Vyas, D
    Wong, TW
    Zhang, GF
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U12 - U12
  • [4] TRANSMODULATION OF HER2 LEVELS BY HER1 ACTIVATION
    WORTHYLAKE, B
    WILEY, HS
    MOLECULAR BIOLOGY OF THE CELL, 1995, 6 : 1374 - 1374
  • [5] New dual inhibitors of HER1 and HER2 protein tyrosine kinases.
    Vite, GD
    Mastalerz, H
    Fink, BE
    Gavai, AV
    Hunt, JT
    Tokarski, JS
    Vyas, DM
    Wong, TW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U3 - U3
  • [6] BMS-599626: A novel dual inhibitor of HER1 and HER2 protein tyrosine kinases.
    Gavai, AV
    Fink, BE
    Tokarski, JS
    Fairfax, D
    Martin, G
    Grubb, L
    Fu, Z
    Kim, SH
    Leavitt, K
    Mastalerz, H
    Mitt, T
    Hunt, JT
    Kadow, JF
    Du, KR
    Han, WC
    Norris, D
    Goyal, B
    Vyas, DM
    Yu, C
    Oppenheimer, S
    Zhang, HJ
    Lee, FY
    Wong, TW
    Vite, GD
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U108 - U108
  • [7] Dual HER2 inhibition
    Landman, Allison
    LANCET ONCOLOGY, 2023, 24 (07): : 724 - 724
  • [8] HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?
    Freeman, MR
    CANCER CELL, 2004, 6 (05) : 427 - 428
  • [9] Histopathologic and immunohistochemical findings of skin rash to HER1 and HER1/2 inhibitors during anticancer therapy
    Nardone, B.
    Kaklamani, V. G.
    Nicholson, K. M.
    Newman, M.
    Guitart, J.
    Gerami, P.
    Talarico, N.
    Rademarker, A.
    West, D. P.
    Lacouture, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Ultrasensitive assay of HER1, HER2, and heregulin- α in whole blood
    Staden, Raluca-Ioana Stefan-van
    Musat, Oana-Raluca
    Gheorghe, Damaris-Cristina
    Ilie-Mihai, Ruxandra-Maria
    Negut, Catalina Cioates
    Sfirloaga, Paula
    TALANTA OPEN, 2022, 6